The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Ingrid Egeland ChristensenIngrid JyssumAnne Therese TveterJoseph SextonTrung T TranSiri MjaalandGrete Birkeland KroTore K KvienDavid John WarrenJørgen JahnsenLudvig A MuntheEspen A HaavardsholmJohn Torgils VaageGunnveig GrødelandFridtjof Lund-JohansenKristin Kaasen JørgensenSilje Watterdal SyversenGuro Løvik GollSella Aarrestad ProvanPublished in: BMC medicine (2022)
Within 4 months after vaccination, antibody levels declined considerably in both IMID patients and controls. Patients had lower initial antibody levels and a more pronounced decline compared to healthy controls and were therefore more likely to decline to low antibody levels. These results support that IMID patients need additional vaccine doses at an earlier stage than healthy individuals.